This story has been updated from a previous version to include comments from Tacere's CEO.

By Doug Macron

Pfizer has exercised its option to develop and commercialize Tacere Therapeutics' expressed RNAi-based hepatitis C treatment, triggering the payment of an undisclosed option fee, Tacere said last week.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.